Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542775 | 0.89 | UTS2R (0.52) | UTS2RMEN1ALDH1A1KMT2A | |
| SCHEMBL6542032 | 0.82 | HTR6 (0.61) | HTR6UTS2RMEN1ALDH1A1KMT2A | |
| SCHEMBL6542559 | 0.81 | PPARG (0.48) | UTS2RMEN1ALDH1A1KMT2A | |
| SCHEMBL6542576 | 0.81 | UTS2R (0.60) | UTS2RMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6541415 | 0.81 | UTS2R (0.48) | UTS2RMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6542101 | 0.81 | HSD17B1 (0.50) | HTR6UTS2RMEN1ALDH1A1KMT2A | |
| SCHEMBL6542115 | 0.81 | UTS2R (0.48) | UTS2REDNRAKDM4EMEN1ALDH1A1 | |
| SCHEMBL6541222 | 0.81 | PTGES2 (0.49) | UTS2RKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6542588 | 0.79 | UTS2R (0.48) | HTR6UTS2RALDH1A1 | |
| SCHEMBL6542141 | 0.79 | UTS2R (0.49) | UTS2RKDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | claimed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | disclosed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100580-A1 | Urotensin-II receptor antagonists | UTS2R, TMPRSS4, PLAUR | HTR6 669/4885UTS2R 1/4885WDR5 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.